Literature DB >> 21916917

Airway angiogenesis in stable and exacerbated chronic obstructive pulmonary disease.

S S Kristan1, M M Marc, I Kern, M Flezar, S Suskovic, M Kosnik, P Korosec.   

Abstract

Angiogenesis is a prominent feature of structural tissue remodelling that occurs in chronic airway diseases, including chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate the airway levels of VEGF, angiogenin, IL-8 and TNF-α in patients with COPD during the stable phase and during acute exacerbation of the disease. We analysed induced sputum samples from 28 patients with COPD. Thirteen of these patients were followed up and second samples of sputum were obtained during acute exacerbation of the disease. The two control groups consisted of 12 healthy smokers and seven healthy non-smokers, all with normal lung function tests. Concentrations of VEGF, angiogenin, IL-8, TNF-α and bFGF were measured by cytometric bead array. In the induced sputum of patients with stable COPD, concentrations of VEGF (P < 0.001, P = 0.02), angiogenin (P < 0.0001, P < 0.0001), IL-8 (P < 0.0001, P = 0.0021) and TNF-α (P < 0.001, P = 0.03) were significantly elevated in comparison with healthy smokers and non-smokers. No additional elevation of angiogenic factors was demonstrated at the time of exacerbation. There was a significant negative correlation between FEV1 and VEGF (P < 0.05, r = -0.38), angiogenin (P < 0.0001, r = -0.68) and IL-8 (P < 0.001, r = -0.54) among smokers (smoking COPD patients and healthy smokers). No significant differences were observed between groups of healthy smokers and non-smokers. These results showed increased airway angiogenesis in patients with COPD. Moreover, VEGF, IL-8 and angiogenin negatively correlated with pulmonary function, which suggests their important role in COPD airway remodelling. However, no additional angiogenic activation was found during exacerbation of COPD.
© 2011 The Authors. Scandinavian Journal of Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21916917     DOI: 10.1111/j.1365-3083.2011.02623.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  6 in total

1.  Basic fibroblast growth factor activates β-catenin/RhoA signaling in pulmonary fibroblasts with chronic obstructive pulmonary disease in rats.

Authors:  Zhengxing Ge; Bo Li; Xun Zhou; Yi Yang; Jun Zhang
Journal:  Mol Cell Biochem       Date:  2016-10-13       Impact factor: 3.396

Review 2.  Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells.

Authors:  Renat Shaykhiev; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2014-12

Review 3.  Angiogenesis, Lymphangiogenesis, and Inflammation in Chronic Obstructive Pulmonary Disease (COPD): Few Certainties and Many Outstanding Questions.

Authors:  Remo Poto; Stefania Loffredo; Francesco Palestra; Gianni Marone; Vincenzo Patella; Gilda Varricchi
Journal:  Cells       Date:  2022-05-23       Impact factor: 7.666

4.  Elevated Serum Interleukin-8 Level as a Preferable Biomarker for Identifying Uncontrolled Asthma and Glucocorticosteroid Responsiveness.

Authors:  Jingxi Zhang; Chong Bai
Journal:  Tanaffos       Date:  2017-06

5.  Bcl10 Regulates Lipopolysaccharide-Induced Pro-Fibrotic Signaling in Bronchial Fibroblasts from Severe Asthma Patients.

Authors:  Rakhee K Ramakrishnan; Khuloud Bajbouj; Maha Guimei; Surendra Singh Rawat; Zaina Kalaji; Mahmood Y Hachim; Bassam Mahboub; Saleh M Ibrahim; Rifat Hamoudi; Rabih Halwani; Qutayba Hamid
Journal:  Biomedicines       Date:  2022-07-15

6.  Critical COPD respiratory illness is linked to increased transcriptomic activity of neutrophil proteases genes.

Authors:  Raquel Almansa; Lorenzo Socias; Monica Sanchez-Garcia; Ignacio Martín-Loeches; Milagros del Olmo; David Andaluz-Ojeda; Felipe Bobillo; Lucia Rico; Agueda Herrero; Vicente Roig; C Alicia San-Jose; Sara Rosich; Julia Barbado; Carlos Disdier; Raúl Ortiz de Lejarazu; Maria C Gallegos; Victoria Fernandez; Jesus F Bermejo-Martin
Journal:  BMC Res Notes       Date:  2012-08-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.